Savara, Inc. (NASDAQ:SVRA) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$149.5M raised Use of proceeds: Accelerate investment in preparing for potential commercialization of MOLBREEVI | Nov 12, 2025 |
| Royalty on U.S. net sales of MOLBREEVI Announced: US$75M Buyers: RTW ($75 million royalty funding; tiered single digit percentage of annual U.S. net sales of MOLBREEVI, subject to a cap) Use of proceeds: Support the potential U.S. launch and commercialization of MOLBREEVI in autoimmune PAP | Oct 29, 2025 |